论文部分内容阅读
目的:探究治疗丙型肝炎肝硬化疾病的有效抗病毒治疗措施。方法:选择2015年1月-2016年1月我院收治的54例丙型肝炎肝硬化者为研究对象,依照代偿与失代偿情况,分为两组,失代偿者使用100万U赛若金联合600mg/d利巴韦林实施治疗,相隔一天治疗一次,后逐渐增加药物使用量。代偿期者使用67.54g/周派罗欣联合600mg/d利巴韦林治疗,对比患者治疗前后HCV RNA、ALT、CHE、AST等指标。结果:治疗3个月之后,失代偿期者的CHE、HCV RNA、ALT、AST、TBIL水平无显著差别,P>0.05.治疗6个月后,CHE、HCV RNA、ALT、AST下降显著,P<0.05.但TBIL和治疗前相比无显著差异。治疗三个月后,代偿期者HCV RNA、ALT、AST、TBIL与治疗前比,无显著差异,P>0.05.治疗6个月后,上述指标得到显著改善。结论:对于代偿期和失代偿期丙型肝炎肝硬化者,使用小剂量逐步加量法对其加以治疗,可以取得较为满意的临床效果,值得进一步推广使用。
Objective: To explore effective anti-viral treatment for the treatment of hepatitis C cirrhosis. Methods: 54 patients with hepatitis C cirrhosis admitted in our hospital from January 2015 to January 2016 were selected as the study subjects, and were divided into two groups according to the decompensation and decompensation. The decompensated persons used 1 million U Race gold if combined with 600mg / d ribavirin treatment, separated by a day treatment, and gradually increase the amount of drugs. Patients with decompensation use 67.54g / week Pei Luo Xin combined with 600mg / d ribavirin treatment, before and after treatment of patients with HCV RNA, ALT, CHE, AST and other indicators. Results: There was no significant difference in CHE, HCV RNA, ALT, AST and TBIL after 3 months of treatment, P> 0.05. After 6 months of treatment, CHE, HCV RNA, ALT and AST decreased significantly, P <0.05, but no significant difference between TBIL and before treatment. Three months after treatment, there was no significant difference between the compensated patients with HCV RNA, ALT, AST, TBIL and before treatment, P> 0.05. After 6 months of treatment, the above indexes were significantly improved. Conclusion: For decompensated and decompensated hepatitis C cirrhosis, the use of a small dose of step by step to treat it, you can get more satisfactory clinical results, it is worth further promotion.